These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Is lansoprazole (Prevacid) or omeprazole (Prilosec) more effective in treating erosive esophagitis? Kim JD J Fam Pract; 2002 Apr; 51(4):384. PubMed ID: 11978268 [No Abstract] [Full Text] [Related]
24. Unusual presentation of mucosal hypersensitivity secondary to gastroesophageal reflux disease. Baron TH; Richter JE; Singh S; Tennyson GS; Andres JM Am J Gastroenterol; 1993 Feb; 88(2):289-92. PubMed ID: 8424436 [TBL] [Abstract][Full Text] [Related]
25. Treatment interruptus: the need for withdrawal. Hassall E Am J Gastroenterol; 2007 Sep; 102(9):2108-9. PubMed ID: 17727443 [No Abstract] [Full Text] [Related]
26. pH, healing rate, and symptom relief in patients with GERD. Huang JQ; Hunt RH Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580 [TBL] [Abstract][Full Text] [Related]
27. [Therapeutic strategies in non-erosive gastro-oesophageal reflux disease]. Domínguez Antonaya M; Moreno Sánchez D; González Alonso R Med Clin (Barc); 2004 Sep; 123(9):352-6. PubMed ID: 15388040 [No Abstract] [Full Text] [Related]
28. Low-dose omeprazole for erosive esophagitis. Epling J; Taylor H J Fam Pract; 1999 Feb; 48(2):93-4. PubMed ID: 10037536 [No Abstract] [Full Text] [Related]
29. Cisapride for nocturnal heartburn. Med Lett Drugs Ther; 1994 Feb; 36(915):11-3. PubMed ID: 8283956 [No Abstract] [Full Text] [Related]
30. High prevalence of reflux oesophagitis among upper endoscopies of Iranian patients. Rezailashkajani M; Roshandel D; Shafaee S; Zali MR Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):499-506. PubMed ID: 17489061 [TBL] [Abstract][Full Text] [Related]
31. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Moore DJ; Tao BS; Lines DR; Hirte C; Heddle ML; Davidson GP J Pediatr; 2003 Aug; 143(2):219-23. PubMed ID: 12970637 [TBL] [Abstract][Full Text] [Related]
32. [Retrosternal pain. Clinical conference about a subject with esophagitis]. Loizeau E Rev Med Suisse Romande; 1993 Jul; 113(7):557-60. PubMed ID: 8367651 [No Abstract] [Full Text] [Related]
33. [Omeprazole. An effective antisecretory agent in ulcerative disease and reflux esophagitis]. Lauritsen K; Laursen LS; Madsen JR Ugeskr Laeger; 1989 Jul; 151(28):1831-3. PubMed ID: 2773093 [No Abstract] [Full Text] [Related]
34. [Reflux disease: the concept, clinical manifestations, diagnosis and treatment]. Ryss ES; Fishzon-Ryss IuI Ter Arkh; 1994; 66(2):80-2. PubMed ID: 8160155 [No Abstract] [Full Text] [Related]
35. [Gastroesophageal reflux disease and reflux esophagitis. Therapeutic modifiability by bethanechol chloride]. Hunold W ZFA (Stuttgart); 1982 Oct; 58(29):1623-8. PubMed ID: 6129755 [No Abstract] [Full Text] [Related]
36. [Gastro-esophageal reflux. Treatment with Gaviscon]. Ferrier JP; Chevrel B Med Chir Dig; 1978; 7(1):73-6. PubMed ID: 642629 [No Abstract] [Full Text] [Related]
37. Present and potential therapies for reflux esophagitis. Hogan WJ; Dodds WJ; Condon RE Wis Med J; 1977 Apr; 76(4):S60-2. PubMed ID: 855362 [No Abstract] [Full Text] [Related]
38. Optimal dose of omeprazole in infants and children. Alliët P; Raes M; Gillis P; Zimmermann A J Pediatr; 1994 Feb; 124(2):332-4. PubMed ID: 8301451 [No Abstract] [Full Text] [Related]